Metastatic colorectal cancer: From improved survival to potential cure

Oncology

Volumn 78, Issue 3-4, 2010, Pages 237-248

  Gallagher, David J ^a   Kemeny, Nancy ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Curative intent; Metastatic colorectal cancer; Resectability

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; HUMAN; INOPERABLE CANCER; METASTASIS; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CATHETER ABLATION; COLONIC NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; MALE; MEDICAL ONCOLOGY; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77952994052     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315730     Document Type: Review

References (159)

1. Paget S: The distribution of secondary growths in cancer of the breast. Lancet 1889; 133: 571-573.
2. Paku S, Dome B, Toth R, Timar J: Organspecificity of the extravasation process: an ultrastructural study. Clin Exp Metastasis 2000; 18: 481-492.
3. Lalor PF, Lai WK, Curbishley SM, Shetty S, Adams DH: Human hepatic sinusoidal endothelial cells can be distinguished by expression of phenotypic markers related to their specialised functions in vivo. World J Gastroenterol 2006; 12: 5429-5439.
4. Hart IR, Fidler IJ: Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res 1980; 40: 2281-2287.
5. Fidler IJ, Poste G: The seed and soil hypothesis revisited. Lancet Oncol 2008; 9: 808.
6. Nguyen DX, Bos PD, Massague J: Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9: 274-284.
7. Chambers AF, Groom AC, MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563-572.
8. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
9. Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-170.
10. Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-532.
11. Samuels Y, Wang Z, Bardelli A, et al: High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554. (Pubitemid 38541907)
12. Baker SJ, Fearon ER, Nigro JM, et al: Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989; 244: 217-221.
13. Markowitz S, Wang J, Myeroff L, et al: Inactivation of the type II TGF- receptor in colon cancer cells with microsatellite instability. Science 1995; 268: 1336-1338.
14. Heidelberger C, Chaudhuri NK, Danneberg P, et al: Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957; 179: 663-666.
15. Sullivan RD, Norcross JW, Watkins E Jr: Chemotherapy of metastatic liver cancer by prolonged hepatic-artery infusion. N Engl J Med 1964; 270: 321-327.
16. Zhang ZG, Harstrick A, Rustum YM: Modulation of fluoropyrimidines: role of dose and schedule of leucovorin administration. Semin Oncol 1992; 19: 10-15.
17. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306: 752-755.
18. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. J Clin Oncol 1992; 10: 904-911.
19. de Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15: 808-815.
20. Van Cutsem E, Twelves C, Cassidy J, et al: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19: 4097-4106.
21. Cassidy J, Twelves C, Van Cutsem E, et al: First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/ leucovorin. Ann Oncol 2002; 13: 566-575.
22. Twelves C, Gollins S, Grieve R, Samuel L: A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 2006; 17: 239-245.
23. Mayer RJ: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? J Clin Oncol 2007; 25: 4165-4167.
24. Shirasaka T: Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol 2009; 39: 2-15.
25. Ezzeldin HH, Diasio RB: Predicting fluorouracil toxicity: can we finally do it? J Clin Oncol 2008; 26: 2080-2082.
26. Haller DG, Cassidy J, Clarke SJ, et al: Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008; 26: 2118-2123.
27. Schwab M, Zanger UM, Marx C, et al: Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008; 26: 2131-2138.
28. Longley DB, Allen WL, Johnston PG: Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim Biophys Acta 2006; 1766: 184-196.
29. Tokunaga Y, Hosogi H, Hoppou T, Nakagami M, Tokuka A, Ohsumi K: Prognostic value of thymidine phosphorylase/platelet-derived endothelial cell growth factor in advanced colorectal cancer after surgery: evaluation with a new monoclonal antibody. Surgery 2002; 131: 541-547.
30. Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6: 1322-1327.
31. Metzger R, Danenberg K, Leichman CG, et al: High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998; 4: 2371-2376.
32. Matsuyama R, Togo S, Shimizu D, et al: Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. Int J Cancer 2006; 119: 406-413.
33. Kohne CH, van Cutsem E, Wils J, et al: Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or with -out irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23: 4856-4865.
34. Beutler E: Targeted disruption of the HFE gene. Proc Natl Acad Sci USA 1998; 95: 2033-2034.
35. Innocenti F, Undevia SD, Iyer L, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382-1388.
36. Cecchin E, Innocenti F, DAndrea M, et al: Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 2009; 27: 2457-2465.
37. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
38. Cassidy J, Clarke S, Diaz-Rubio E, et al: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-2012.
39. Fuchs CS, Marshall J, Mitchell E, et al: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25: 4779-4786.
40. Grothey A, Sargent D, Goldberg RM, Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214.
41. Falcone A, Ricci S, Brunetti I, et al: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as firstline treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676.
42. Seymour MT, Maughan TS, Ledermann JA, et al: Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370: 143-152.
43. Koopman M, Antonini NF, Douma J, et al: Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007; 370: 135-142.
44. O'Neil BH, Goldberg RM: Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials. Oncologist 2008; 13: 1074-1083.
45. Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
46. Colucci G, Gebbia V, Paoletti G, et al: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell Italia Meridionale. J Clin Oncol 2005; 23: 4866-4875.
47. Tournigand C, Cervantes A, Figer A, et al: OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer -a GERCOR study. J Clin Oncol 2006; 24: 394-400.
48. Maindrault-Goebel F, Lledo G, Chibaudel B, et al: Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): a GERCOR study. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(No 18S, suppl):4013.
49. Labianca R FI, Cortesi E, et al: Alternating versus continuous FOLFIRI in advanced colorectal cancer (ACC): a randomized GISCAD trial. ASCO Annu Meet Proc, pt 1. J Clin Oncol 2006; 24(No 18S, suppl):3505.
50. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
51. Saltz LB, Clarke S, Diaz-Rubio E, et al: Bevacizumab in combination with oxaliplatinbased chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
52. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
53. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
54. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544.
55. Grothey A SM, Hedrick E, Purdie D, Yi J, Dong W, Kozloff M; and the BRiTE Study Investigators: Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; 25(No 18S, suppl):4036.
56. Van Cutsem E, Rivera F, Berry S, et al: Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009;20:1842-1847. Epub 2009 Apr 30
57. Rini BI SJ, Fruehauf JP, et al: Association of diastolic blood pressure (dBP) 1 90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736). J Clin Oncol 2008; 26(suppl):3543.
58. Schneider BP, Wang M, Radovich M, et al: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008; 26: 4672-4678.
59. Burstein HJ, Chen YH, Parker LM, et al: VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 2008; 14: 7871-7877.
60. Jubb AM, Hurwitz HI, Bai W, et al: Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006; 24: 217-227.
61. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH: Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab -an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008; 14: 1407-1412.
62. Rini BI, Michaelson MD, Rosenberg JE, et al: Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumabrefractory metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 3743-3748.
63. Willett CG, Duda DG, di Tomaso E, et al: Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009; 27: 3020-3026.
64. Jain RK, Duda DG, Willett CG, et al: Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009; 6: 327-338.
65. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
66. Van Cutsem E NM, Lang I, Cascinu S, Shchepotin I, Maurel J, Rougier P, Cunningham D, Nippgen J, Köhne C: Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; 25(No 18S, suppl):4000.
67. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
68. Van Cutsem E, Peeters M, Siena S, et al: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664.
69. Hudis CA: Trastuzumab -mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51.
70. Cameron DA, Stein S: Drug insight: intracellular inhibitors of HER2 -clinical development of lapatinib in breast cancer. Nat Clin Pract Oncol 2008; 5: 512-520.
71. Chung KY, Shia J, Kemeny NE, et al: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-1810.
72. Penault-Llorca F, Cayre A, Arnould L, et al: Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment? Oncol Rep 2006; 16: 1173-1179.
73. Francoual M, Etienne-Grimaldi MC, Formento JL, et al: EGFR in colorectal cancer: more than a simple receptor. Ann Oncol 2006; 17: 962-967.
74. Lievre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995.
75. Moroni M, Veronese S, Benvenuti S, et al: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279-286.
76. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al: Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24: 4914-4921.
77. De Roock W, Piessevaux H, De Schutter J, et al: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19: 508-515.
78. Di Fiore F, Blanchard F, Charbonnier F, et al: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007; 96: 1166-1169.
79. Frattini M, Saletti P, Romagnani E, et al: PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007; 97: 1139-1145.
80. Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-3237.
81. Amado RG, Wolf M, Peeters M, et al: Wildtype KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
82. Douillard J, Siena S, Cassidy J, et al: Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (Tx) for metastatic colorectal cancer (mCRC): the PRIME trial; in ESMO 2009, Berlin, 2009.
83. Peeters MPT, Hotko Y, et al: Randomized phase 3 study of panitumumab with FOLFIRI versus FOLFIRI alone as second-line treatment (Tx) in patients (pts) with metastatic colorectal cancer (mCRC); in ESMO 2009, Berlin, 2009.
84. Van Cutsem ELI, D haens G, Moiseyenko V, Zaluski J, Folprecht G, Tejpar S, Kisker O, Stroh C, Rougier P: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol 2008; 26:(May 20 suppl; abstr 2).
85. Saltz LB, Lenz HJ, Kindler HL, et al: Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007; 25: 4557-4561.
86. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, Shahin S, Griffin T: An updated analysis of safety and efficacy of oxaliplatin (OX)/bevacizumab (BEV) +/-panitumumab (PMAB) for first-line treatment (Tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). Proc Am Soc Clin Oncol (Gastrointestinal Symposium) 2008:abstract 273.
87. Punt CJ, Tol J, Rodenburg CJ, Cats A, Creemers G, Schrama JG, Erdkamp FL, Vos A, Mol L, Antonini NF: Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 2008; 26:(May 20 suppl; abstr. LBA 4011).
88. Tol J, Koopman M, Cats A, et al: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-572.
89. Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671.
90. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009; 101: 1308-1324.
91. Laurent-Puig P, Cayre A, Manceau G, et al: Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27: 5924-5930.
92. Kohne CH, Lenz HJ: Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist 2009; 14: 478-488.
93. Choti MA, Sitzmann JV, Tiburi MF, et al: Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235: 759-766.
94. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D: Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006; 13: 1271-1280.
95. Gallagher DJ, Zheng J, Capanu M, et al: Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases. Ann Surg Oncol 2009; 16: 1844-1851.
96. Nordlinger B, Vaillant JC, Guiguet M, et al: Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Française de Chirurgie. J Clin Oncol 1994; 12: 1491-1496.
97. Scheele J, Stangl R, Altendorf-Hofmann A: Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990; 77: 1241-1246.
98. Adam R, Delvart V, Pascal G, et al: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-657; discussion 57-58.
99. Adam R, Pascal G, Castaing D, et al: Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240: 1052-1061; discussion 61-64.
100. Nordlinger BSH, Collette L, et al: Final results of the EORTC Intergroup randomized phase III study 40983 (EPOC) evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(No 18S, suppl): LBA5.
101. Portier G, Elias D, Bouche O, et al: Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24: 4976-4982.
102. Parks R, Gonen M, Kemeny N, et al: Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg 2007; 204: 753-761; discussion 61-63.
103. Tanaka K, Shimada H, Ueda M, Matsuo K, Endo I, Togo S: Role of hepatectomy in treating multiple bilobar colorectal cancer metastases. Surgery 2008; 143: 259-270.
104. Wang X, Hershman DL, Abrams JA, et al: Predictors of survival after hepatic resection among patients with colorectal liver metastasis. Br J Cancer 2007; 97: 1606-1612.
105. Mitry E, Fields AL, Bleiberg H, et al: Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008; 26: 4906-4911.
106. Petrelli NJ: Perioperative or adjuvant therapy for resectable colorectal hepatic metastases. J Clin Oncol 2008; 26: 4862-4863.
107. Iwatsuki S, Dvorchik I, Madariaga JR, et al: Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 1999; 189: 291-299.
108. Nordlinger B, Guiguet M, Vaillant JC, et al: Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1,568 patients. Association Française de Chirurgie. Cancer 1996; 77: 1254-1262.
109. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1,001 consecutive cases. Ann Surg 1999; 230: 309-318; discussion 18-21.
110. Lise M, Bacchetti S, Da Pian P, Nitti D, Pilati P: Patterns of recurrence after resection of colorectal liver metastases: prediction by models of outcome analysis. World J Surg 2001; 25: 638-644.
111. Ueno H, Mochizuki H, Hashiguchi Y, Hase K: Prognostic determinants of patients with lateral nodal involvement by rectal cancer. Ann Surg 2001; 234: 190-197.
112. Breedis C, Young G: The blood supply of neoplasms in the liver. Am J Pathol 1954; 30: 969-977.
113. Ensminger WD, Rosowsky A, Raso V, et al: A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2- -deoxyuridine and 5-fluorouracil. Cancer Res 1978; 38: 3784-3792.
114. Ensminger W, Niederhuber J, Dakhil S, Thrall J, Wheeler R: Totally implanted drug delivery system for hepatic arterial chemotherapy. Cancer Treat Rep 1981; 65: 393-400.
115. Allen PJ, Nissan A, Picon AI, et al: Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg 2005; 201: 57-65.
116. Kemeny N, Seiter K, Niedzwiecki D, et al: A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 1992; 69: 327-334.
117. Mocellin S, Pilati P, Lise M, Nitti D: Metaanalysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol 2007; 25: 5649-5654.
118. Kemeny NE, Niedzwiecki D, Hollis DR, et al: Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006; 24: 1395-1403.
119. Kemeny NE, Melendez FD, Capanu M, et al: Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2009; 27: 3465-3471.
120. Huitzil FDCM, Paty P, DAngelica M, Fong Y, Jarnagin W, Patel D, Kemeny N: Predictive factors for resection of unresectable metastases from colorectal cancer in patients treated with hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (DEX) plus IV oxaliplatin (Oxali) and irinotecan (CPT). Proc Am Soc Clin Oncol (Gastrointestinal Symposium), Orlando, 2008.
121. Kemeny N, Huang Y, Cohen AM, et al: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341: 2039-2048.
122. Kemeny NE, Gonen M: Hepatic arterial infusion after liver resection. N Engl J Med 2005; 352: 734-735.
123. Stang A, Fischbach R, Teichmann W, Bokemeyer C, Braumann D: A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. Eur J Cancer 2009; 45: 1748-1756.
124. Wong SL, Mangu PB, Choti MA, et al: American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 2010; 28: 493-508.
125. Solbiati L, Livraghi T, Goldberg SN, et al: Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001; 221: 159-166.
126. Gillams A, Cassoni A, Conway G, Lees W: Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging 2005; 30: 435-441.
127. Jakobs TF, Hoffmann RT, Trumm C, Reiser MF, Helmberger TK: Radiofrequency ablation of colorectal liver metastases: midterm results in 68 patients. Anticancer Res 2006; 26: 671-680.
128. Amersi FF, McElrath-Garza A, Ahmad A, et al: Long-term survival after radiofrequency ablation of complex unresectable liver tumors. Arch Surg 2006; 141: 581-587; discussion 7-8.
129. Abitabile P, Hartl U, Lange J, Maurer CA: Radiofrequency ablation permits an effective treatment for colorectal liver metastasis. Eur J Surg Oncol 2007; 33: 67-71.
130. Siperstein AE, Berber E, Ballem N, Parikh RT: Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 2007; 246: 559-565; discussion 65-67.
131. Sorensen SM, Mortensen FV, Nielsen DT: Radiofrequency ablation of colorectal liver metastases: long-term survival. Acta Radiol 2007; 48: 253-258.
132. Veltri A, Sacchetto P, Tosetti I, Pagano E, Fava C, Gandini G: Radiofrequency ablation of colorectal liver metastases: small size favorably predicts technique effectiveness and survival. Cardiovasc Intervent Radiol 2008; 31: 948-956.
133. Gillams AR, Lees WR: Five-year survival following radiofrequency ablation of small, solitary, hepatic colorectal metastases. J Vasc Interv Radiol 2008; 19: 712-717.
134. Oshowo A, Gillams A, Harrison E, Lees WR, Taylor I: Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg 2003; 90: 1240-1243. (Pubitemid 37330428)
135. Aloia TA, Vauthey JN, Loyer EM, et al: Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 2006; 141: 460-466; discussion 6-7.
136. White RR, Avital I, Sofocleous CT, et al: Rates and patterns of recurrence for percutaneous radiofrequency ablation and open wedge resection for solitary colorectal liver metastasis. J Gastrointest Surg 2007; 11: 256-263.
137. Park IJ, Kim HC, Yu CS, Kim PN, Won HJ, Kim JC: Radiofrequency ablation for metachronous liver metastasis from colorectal cancer after curative surgery. Ann Surg Oncol 2008; 15: 227-232.
138. Hur H, Ko YT, Min BS, et al: Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg 2009; 197: 728-736.
139. Pawlik TM, Izzo F, Cohen DS, Morris JS, Curley SA: Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol 2003; 10: 1059-1069.
140. Elias D, Baton O, Sideris L, et al: Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases. J Surg Oncol 2005; 90: 36-42.
141. Kornprat P, Jarnagin WR, DeMatteo RP, Fong Y, Blumgart LH, DAngelica M: Role of intraoperative thermoablation combined with resection in the treatment of hepatic metastasis from colorectal cancer. Arch Surg 2007; 142: 1087-1092.
142. Abdalla EK, Vauthey JN, Ellis LM, et al: Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239: 818-825; discussion 25-27.
143. Ruers TJ, Joosten JJ, Wiering B, et al: Comparison between local ablative therapy and chemotherapy for non-resectable colorectal liver metastases: a prospective study. Ann Surg Oncol 2007; 14: 1161-1169.
144. Tomlinson I, Webb E, Carvajal-Carmona L, et al: A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet 2007; 39: 984-988.
145. Berndt SI, Potter JD, Hazra A, et al: Pooled analysis of genetic variation at chromosome 8q24 and colorectal neoplasia risk. Hum Mol Genet 2008; 17: 2665-2672.
146. Zanke BW, Greenwood CM, Rangrej J, et al: Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet 2007; 39: 989-994.
147. Tenesa A, Farrington SM, Prendergast JG, et al: Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet 2008; 40: 631-637.
148. Broderick P, Carvajal-Carmona L, Pittman AM, et al: A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nat Genet 2007; 39: 1315-1317.
149. Tomlinson IP, Webb E, Carvajal-Carmona L, et al: A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet 2008; 40: 623-630. (Pubitemid 351601204)
150. Houlston RS, Webb E, Broderick P, et al: Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet 2008; 40: 1426-1435.
151. Kida Y, Han YP: MicroRNA expression in colon adenocarcinoma. JAMA 2008; 299: 2628; author reply 2628-2629.
152. Valeri N, Croce CM, Fabbri M: Pathogenetic and clinical relevance of MicroRNAs in colorectal cancer. Cancer Genomics Proteomics 2009; 6: 195-204.
153. Schetter AJ, Leung SY, Sohn JJ, et al: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA
154. Cohen SJ, Punt CJ, Iannotti N, et al: Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 2009; 20: 1223-1229.
155. Leversha MA, Han J, Asgari Z, et al: Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res 2009; 15: 2091-2097.
156. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
157. De Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
158. Van Cutsem E, Kohne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-1417.
159. Hecht JR, Mitchell E, Chidiac T, et al: A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27:672-680.